Business · 11/02/2004Updated: 10/17/2026 · 1 min read
FDA Requests Comments on Draft Guidance for Postmenopausal Osteoporosis Treatment
Summary
The FDA is seeking public input on a draft guidance document related to the evaluation of agents used to prevent or treat postmenopausal osteoporosis, following a decade of new research on the topic.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →